research use only
Cat.No.S4862
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Fungal Inhibitors | Cycloheximide Tolnaftate Manogepix (E1210) Amorolfine HCl Isavuconazole Juglone Bifonazole Thimerosal Pseudolaric Acid B Butylparaben |
|
In vitro |
Ethanol : 100 mg/mL
DMSO
: Insoluble
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 410.72 | Formula | C30H50 |
Storage (From the date of receipt) | 2 years -20°C liquid |
|---|---|---|---|---|---|
| CAS No. | 111-02-4 | -- | |||
Read more about storage stability stock solution CAS number
| In vitro |
Squalene is a triterpene that is an intermediate in the cholesterol biosynthesis pathway. In vitro experimental evidence indicates that this compound is a highly effective oxygen-scavenging agent and possesses antioxidant properties.
|
|---|---|
| In vivo |
Squalene appears to be critical in reducing free radical oxidative damage to the skin. It can effectively inhibit chemically induced skin tumorigenesis in rodents.
|
References |
(data from https://clinicaltrials.gov, updated on 2022-11-17)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05035680 | WITHDRAWN | Influenza |
Gates Medical Research Institute |
2022-07-14 | PHASE1 |
| NCT05228314 | COMPLETED | COVID-19 |
Clover Biopharmaceuticals AUS Pty |
2022-05-30 | PHASE1 |
| NCT04753892 | COMPLETED | Healthy |
Imperial College London |
2021-09-10 | |
| NCT04555044 | Completed | Essential Fatty Acid Deficiency (EFAD) |
Baxter Healthcare Corporation |
2021-01-22 | Phase 4 |
| NCT03563222 | Terminated | Malnutrition Child |
Fresenius Kabi |
2019-12-18 | Phase 4 |
| NCT02476994 | Terminated | Essential Fatty Acid Deficiency (EFAD) |
Baxter Healthcare Corporation |
2015-05 | Phase 4 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.